Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Novavax, Inc.    NVAX

NOVAVAX, INC.

(NVAX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Novavax : Endo starts manufacturing Novavax's potential COVID-19 vaccine

share with twitter share with LinkedIn share with facebook
09/25/2020 | 07:44am EDT
FILE PHOTO: A small bottle labeled with a

Generic drugmaker Endo said on Friday it was manufacturing Novavax Inc's experimental COVID-19 vaccine, sending its shares up 10% before the trading bell.

The news comes a day after Novavax launched a late-stage trial of the vaccine candidate, NVX-CoV2373, in the United Kingdom.

Endo said it has signed a deal with Novavax and its unit Par Sterile has begun production of the final drug product, with initial batches to be used in Novavax's phase-3 clinical trial in the United States.

Financials and other terms of the non-exclusive agreement were not disclosed.

NVX-CoV2373 is currently also being tested in two ongoing mid-stage trials that began in August.

(Reporting by Manas Mishra and Mrinalika Roy in Bengaluru; Editing by Shinjini Ganguli)


Stocks mentioned in the article
ChangeLast1st jan.
ENDO INTERNATIONAL PLC -5.69% 5.47 Delayed Quote.16.63%
NOVAVAX, INC. -7.32% 91.16 Delayed Quote.2,192.96%
share with twitter share with LinkedIn share with facebook
All news about NOVAVAX, INC.
03:49pEcuador signs COVID-19 vaccine supply deals with pharma companies
RE
07:57aNOVAVAX : to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020
AQ
10/20NOVAVAX : to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020
AQ
10/20NOVAVAX : to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 2020
AQ
10/20Novavax to Present COVID-19 Vaccine Data at World Vaccine Congress Europe 202..
GL
10/16EXPLAINER : When will COVID-19 vaccines be generally available in the United Sta..
RE
10/16Look Who's Really Chasing Hot Stocks Like Zoom
DJ
10/14NOVAVAX : Appoints Leadership Team to Advance NanoFlu through Regulatory Licensu..
AQ
10/13Pfizer to enroll kids as young as 12 in COVID-19 vaccine study
RE
10/13NOVAVAX : to explore combined influenza/COVID-19 vaccine for use post pandemic
RE
More news
Financials (USD)
Sales 2020 971 M - -
Net income 2020 442 M - -
Net cash 2020 426 M - -
P/E ratio 2020 13,1x
Yield 2020 -
Capitalization 4 698 M 4 698 M -
EV / Sales 2020 4,40x
EV / Sales 2021 1,42x
Nbr of Employees 359
Free-Float 98,9%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 220,80 $
Last Close Price 91,26 $
Spread / Highest target 218%
Spread / Average Target 142%
Spread / Lowest Target 15,1%
EPS Revisions
Managers
NameTitle
Stanley C. Erck President, Chief Executive Officer & Director
James F. Young Chairman
John J. Trizzino Executive VP, Chief Financial & Business Officer
Gregory M. Glenn President-Research & Development
Biegie Lee Vice President-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
NOVAVAX, INC.2,371.36%5 063
LONZA GROUP AG64.78%47 655
SEAGEN INC.73.31%34 455
IQVIA HOLDINGS INC.12.29%33 260
CELLTRION, INC.34.81%28 816
MODERNA, INC.264.57%28 138